Institute for Cancer Research

Kjetil Taskén
Institute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

Current news and events

Conference October 22 - part of Oslo Innovation Week:Science Impact 2025 – tomorrow's solutions start today

Announcement from UiO Growth House:
Spend a day with great science, innovation and networking opportunities at this meeting place for academia, hospitals, the institute sector, the public sector, start-ups and industry.​ The conference is a part of Oslo Innovation Week 2025. Topics: antimicrobial resistance, cancer, neuroscience, materials science, social innovation, and women's health.
Time and place: Oct. 22, 2025 8:00 AM – 5:00 PM, Oslo Science Park, Gaustadalléen 21, Oslo

Programme and registration (from UiO Growth House)

Open meeting October 14th:Lynch Syndrome – Information and Networking Meeting

Meeting home page
Meeting home page

NORILCO and the Norwegian Cancer Society invite you to an information and networking meeting in collaboration with the PREDI-LYNCH project group. This event plays an important role in strengthening communication between patients and specialists, fostering a sense of community among people with Lynch syndrome, and highlighting ongoing research efforts such as the PREDI-LYNCH project.
There will be lectures by PREDI-LYNCH project coordinator Mev Dominguez-Valentin, as well as OUS researchers Marte Lie Høivik og Kristina Lindemann.

PREDI-LYNCH kickoff meeting in Heidelberg:Bringing Europe together to tackle Lynch syndrome

Mev Dominguez-Valentin welcomes the partners
Mev Dominguez-Valentin welcomes the partners

The PREDI-LYNCH consortium officially launched its six-year Horizon Europe project with an in-person kickoff meeting in Heidelberg on September 18, 2025. The partners were welcomed by Project Coordinator Mev Dominguez-Valentin from the Institute for Cancer Research.
The event brought together more than 50 researchers, clinicians, and partners from across Europe. Funded under the EU Mission on Cancer, PREDI-LYNCH unites leading institutions and experts to improve screening, diagnostics, and risk prediction for individuals with a hereditary predisposition to cancer.

National Research Archive (NVA) Now Available for OUS Researchers

The National Research Archive (NVA) has replaced Cristin and is now open for both previous Cristin users and new contributors at OUS. Whether you're registering for the first time or updating your publications, NVA offers improved functionality for managing research outputs, including support for green open access and project code reporting.

Click More to learn how to get started, request editing access, and upload files for archiving.

Article from Johanna Olweus's group published in Nature Reviews Cancer

Johanna Olweus
Johanna Olweus

The article "Targeting the roots of myeloid malignancies with T cell receptors" has been published online in the prestigious journal Nature Reviews Cancer.
Senior author is Johanna Olweus, head of the Experimental Immunotherapy Group at the Department of Cancer Immunology at the Insitute for Cancer Research.

The work is a collaboration with Sten Eirik Jacobsens group at Karolinska Institutet.

Link to the article (view only version)

Radulovic and Stenmark with lysosome review in Nature Reviews Molecular Cell Biology

Maja Radulovic
Maja Radulovic

Project leader Maja Radulovic and group leader Harald Stenmark at Department of Molecular Cell Biology, Institute for Cancer Research, have recently published a review in Nature Reviews Molecular Cell Biology entitled “Lysosomal membrane homeostasis and its importance in physiology and disease”. The motivation for this review is that lysosomes play a central role in disease progression, including neurodegenerative diseases and cancer, but also offer opportunities for novel therapies.